Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

计划入组 317 人 · 首次发布于 2005 年 9 月 30 日

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

计划入组 185 人 · 首次发布于 2005 年 11 月 21 日

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole

计划入组 40 人 · 首次发布于 2005 年 10 月 12 日

PGR-496

PGR-683

AAV-PGRN(Alexion Pharmaceuticals)

Per Humpert

Germany

Carlsson, Per-Ola

Sweden

Par Pharmaceutical, Inc.

United States

USPTO Director Takes Direct Control of Patent Challenge Reviews, Potentially Strengthening Patent Protection

Patent Trial and Appeal Board Institutes Review Against Halozyme in Merck Patent Dispute

Enveric Biosciences Secures Patent Victory as AbbVie Withdraws Challenge Following $1.2 Billion Gilgamesh Acquisition